Product image of Olmeamlodipinhct Puren (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide) supplied by GNH India

Olmeamlodipinhct Puren

Active Ingredient:
Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide
Origin:
EU

Olmeamlodipinhct Puren (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide, the active ingredient in Olmeamlodipinhct Puren, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension in adults, often when single‑agent therapy is insufficient. GNH India supplies Olmeamlodipinhct Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Olmeamlodipinhct Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Puren Pharma Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmeamlodipinhct Puren is a combination antihypertensive used to manage high blood pressure and related cardiovascular risk factors.

  • Hypertension: lowers systolic and diastolic blood pressure to reduce risk of stroke and heart attack.
  • Hypertensive heart disease: improves cardiac workload and prevents disease progression.
  • Chronic kidney disease with hypertension: slows renal function decline by controlling blood pressure.

How It Works

  • The formulation combines three agents: olmesartan medoxomil blocks the angiotensin II type 1 receptor, reducing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide promotes renal sodium and water excretion, decreasing plasma volume. Together they produce additive blood‑pressure‑lowering effects through vascular resistance reduction and volume depletion.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Dizziness or light‑headedness
  • Peripheral edema
  • Headache
  • Flushing
  • Fatigue
  • Increased urination

Serious or Rare Side Effects

  • Severe hypotension
  • Electrolyte disturbances (e.g., low potassium)
  • Acute kidney injury
  • Angio‑edema
  • Liver enzyme elevation
  • Severe skin reactions such as Stevens‑Johnson syndrome

Precautions & Warnings

When prescribing Olmeamlodipinhct Puren, clinicians should consider several safety aspects.

  • Renal function: assess baseline creatinine and monitor periodically.
  • Electrolytes: check serum potassium and sodium before initiation and during therapy.
  • Cardiovascular status: avoid rapid blood‑pressure fall in patients with aortic stenosis.
  • Pregnancy: contraindicated in the second and third trimesters.
  • Drug hypersensitivity: discontinue if angio‑edema or severe rash develops.
  • Store at below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Olmeamlodipinhct Puren can interact with several medicines, requiring clinical vigilance.

Major Interactions (Avoid)

  • Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal impairment.
  • Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine levels.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
  • Lithium: may increase lithium concentrations.
  • Diuretics other than hydrochlorothiazide: additive electrolyte disturbances.
  • Antidiabetic agents: enhanced glucose‑lowering effect may require dose adjustment.

Frequently Asked Questions

Olmeamlodipinhct Puren is a fixed‑dose combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide indicated for the treatment of hypertension, including patients with hypertensive heart disease or chronic kidney disease where blood‑pressure control is needed.

The three components act together: olmesartan blocks angiotensin‑II receptors to reduce vasoconstriction, amlodipine relaxes arterial smooth muscle by inhibiting calcium entry, and hydrochlorothiazide increases urinary sodium and water loss, lowering plasma volume. This multi‑mechanistic approach produces additive blood‑pressure reduction.

Dosage is individualized by the prescribing clinician based on the patient’s blood‑pressure level, renal function and tolerability. The prescriber determines the appropriate strength and dosing schedule according to clinical guidelines.

Olmesartan medoxomil is contraindicated in the second and third trimesters of pregnancy because of fetal toxicity risk. Amlodipine and hydrochlorothiazide are also not recommended unless clearly needed. Breastfeeding mothers should consult a physician, as the drugs may pass into milk.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy, the combination offers broader blood‑pressure control by targeting three pathways simultaneously, often allowing lower individual drug doses and improving adherence. It may be more effective in patients who do not achieve target pressure with a single agent.

Store the tablets at or below 25 °C in their original packaging, protected from moisture and light. Do not expose to extreme temperatures or humidity to maintain product stability.

Olmeamlodipinhct Puren is taken orally, usually once daily with or without food, as directed by the prescribing healthcare professional.

Serious adverse events include severe hypotension, acute kidney injury, electrolyte imbalances such as hyper‑ or hypokalaemia, angio‑edema and rare severe skin reactions. Patients should be monitored for these conditions, especially during treatment initiation.

The product is contraindicated in patients with known hypersensitivity to any component, in pregnant women beyond the first trimester, and in individuals with severe renal impairment or a history of angio‑edema related to ARB therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT